Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

This article was originally published on Nasdaq

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to loss of $0.21 per share a year ago. These figures are adjusted